Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV) criteria for schizophrenia (295.10, 295.20, 295.30, 295.60, 295.90) for 1 year (the diagnosis will be established using the K-SADS-PL, including all supplements)~* Must not be a danger to themselves or others, and must have family support available to be maintained as an outpatient~* Should have had at least 1 adequate treatment with an antipsychotic before participation in this study~* Must have a PANSS score between 60 and 120, inclusive, at screening and baseline~* Weight \>=29 kg~Exclusion Criteria:~* Meet the DSM-IV criteria at screening for dissociative disorder, bipolar disorder, major depressive disorder, schizoaffective disorder, schizophreniform disorder, autistic disorder, or primary substance induced psychotic disorder. Other comorbid disorders e.g., attention-deficit hyperactivity disorder (ADHD) are allowed as long as the diagnosis of schizophrenia is the primary diagnosis and the comorbid disorders in the investigator's judgment do not require medication~* Mild, moderate, or severe mental retardation (i.e., documented intelligence quotient \[IQ\] \<70) established by previous IQ testing or history~* Women who are pregnant (as confirmed by urine pregnancy test performed at screening or baseline), planning to become pregnant or are nursing~* Have a known or suspected history of seizure disorder, or neuroleptic malignant syndrome, encephalopathic syndrome, tardive dyskinesia, or insulin dependent diabetes mellitus~* Presence of any significant or unstable cardiovascular, respiratory, renal, hepatic, hematologic, endocrine, immunologic, or other systemic disease

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Paliperidone ER 1.5 mg tablet once daily for 6 weeks
- 002 (Type: EXPERIMENTAL): Paliperidone ER 3 mg or 6 mg tablet once daily for 6 weeks
- 003 (Type: EXPERIMENTAL): Paliperidone ER 6 mg or 12 mg tablet once daily for 6 weeks
- 004 (Type: PLACEBO_COMPARATOR): Placebo Once daily for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).